Vyjuvek market forecast points to long-term growth as gene therapy use expands
The Business Research Company says the Vyjuvek market is positioned for sustained expansion through 2035 as gene delivery technology, rare disease research and regulatory support broaden the use of topical gene therapies. North America led the market in 2024, while the report points to growing demand tied to chronic disease prevalence and dermatology-focused genetic treatments.
Why it matters: - Vyjuvek is part of a wider shift toward gene therapies that target rare genetic skin disorders at the source. - The market’s growth signals rising commercial interest in topical and redoable treatments for dystrophic epidermolysis bullosa and related conditions. - Expanding demand could shape investment in dermatology gene delivery, wound-healing therapies and patient-specific rare disease care.
What happened: - The Business Research Company published its VYJUVEK Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Vyjuvek market is gaining momentum as gene therapy advances create new treatment options for rare genetic skin disorders. - North America held the largest share of the Vyjuvek market in 2024. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report also offers a free sample of the Vyjuvek market report and the full Vyjuvek market report.
The details: - Vyjuvek is a topical gene therapy designed to treat dystrophic epidermolysis bullosa, or DEB. - The therapy delivers functional COL7A1 genes directly to damaged skin cells. - Vyjuvek helps stimulate production of type VII collagen, which is essential for skin integrity and wound repair. - The report identifies Vyjuvek as the first redosable gene therapy approved to treat DEB. - Market growth has been driven by gene delivery breakthroughs, deeper understanding of collagen-associated genetic conditions and rare disease research initiatives. - Early trial results for topical gene therapy and supportive regulatory frameworks for breakthrough treatments have also supported adoption. - The report expects continued expansion as more gene therapies gain approval for dermatological use. - Forecast-period trends include wider adoption of topical gene therapies, greater focus on rare genetic skin diseases, more use of redosable gene therapy systems, targeted wound-healing treatments and improved localized gene delivery. - The report says Vyjuvek’s topical gel formulation reinforces skin structure, accelerates wound healing, reduces chronic wound episodes and improves quality of life. - One cited growth driver is the increasing prevalence of chronic diseases worldwide. - The report links that trend to aging populations, unhealthy lifestyles, rapid urbanization and higher exposure to environmental risks. - Allergy UK reported in April 2024 that more than 21 million people in the United Kingdom suffer from allergies, and that allergies were the most frequently reported chronic condition in 2022. - Projections cited in the release suggest half of Europe’s population will experience at least one allergy by 2026.
Between the lines: - The market thesis is broader than one drug: it reflects a larger commercial bet on localized gene delivery for skin disease. - Redosable therapy is a key differentiator because repeat dosing can matter in chronic or recurrent conditions. - The regional lead in North America suggests early commercialization and reimbursement potential may be strongest there first. - The release mixes market analysis with promotional language, so the core takeaway is the forecast direction rather than a single near-term sales milestone.
What's next: - The Business Research Company says future market expansion will depend on additional approvals for dermatology-focused gene therapies. - Investment is likely to keep flowing into topical gene delivery and patient-centric genetic treatment platforms. - The report’s added market-attractiveness scoring, TAM analysis, company scoring matrices, dashboards and hotspot graphics are positioned to support strategic planning in the sector.
The bottom line: - Vyjuvek sits at the intersection of rare disease therapy and next-generation gene delivery, and the report expects that combination to support long-term market growth.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Africa Environmental Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.